40172-65-4
物理化学性质
| 熔点 | 184-188°C |
| 沸点 | 417.1±28.0 °C(Predicted) |
| 密度 | 1.403±0.06 g/cm3(Predicted) |
| 储存条件 | Keep in dark place,Sealed in dry,2-8°C |
| 溶解度 | 二甲基亚砜：≥30mg/mL |
| 酸度系数(pKa) | 3.50±0.30(Predicted) |
| 形态 | 固体 |
| 颜色 | 米白色 |
| 稳定性 | Stable for 1 year as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months. |
| InChI | 1S/C11H8N2S/c12-11-13-10-8-4-2-1-3-7(8)5-6-9(10)14-11/h1-6H,(H2,12,13) |
| InChIKey | FECQXVPRUCCUIL-UHFFFAOYSA-N |
| SMILES | Nc1nc2c(ccc3ccccc23)s1 |
| CAS 数据库 | 40172-65-4(CAS DataBase Reference) |
| EPA化学物质信息 | Naphtho[1,2-d]thiazol-2-amine (40172-65-4) |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H319 |
| 防范说明 | P264-P270-P280-P301+P312-P305+P351+P338-P337+P313 |
| 危险品标志 | Xn |
| 危险类别码 | 20/21/22-36/37/38-36-22 |
| 危险类别码 | R20/21/22-R36/37/38 |
| 安全说明 | 22-36/37/39-26 |
| 安全说明 | S22-S36/37/39 |
| WGK Germany | WGK 3 |
| TSCA | TSCA listed |
| 存储类别 | 11 - Combustible Solids |
| 危险性类别 | Acute Tox. 4 Oral Eye Irrit. 2 |
图谱信息
NAPHTHO[1,2-D]THIAZOL-2-AMINE(40172-65-4)核磁图(1HNMR)NAPHTHO[1,2-D]THIAZOL-2-AMINE(40172-65-4)红外图谱(IR1)NAPHTHO[1,2-D]THIAZOL-2-AMINE(40172-65-4)红外图谱(IR2)NAPHTHO[1,2-D]THIAZOL-2-AMINE价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-111655R | NAPHTHO[1,2-D]THIAZOL-2-AMINE SKA-31 (Standard) | 40172-65-4 | 5 mg | 1500元 |
| 2026/09/15 | HY-111655R | NAPHTHO[1,2-D]THIAZOL-2-AMINE SKA-31 (Standard) | 40172-65-4 | 10 mg | 2250元 |
| 2026/09/15 | HY-111655 | NAPHTHO[1,2-D]THIAZOL-2-AMINE SKA-31 | 40172-65-4 | 5mg | 360元 |
常见问题列表
EC50: 2.9 μM (KCa2.1), 1.9 μM (KCa2.2), 2.9 μM (KCa2.3), 260 nM (KCa3.1)
SKA-31 activates KCa2/3 channels more potently than PK 26124, and is more selective over other Ion channels.
SKA-31 reduces cell viability with IC
50s
of 5.3 μM , 46.9 μM in HCT-116 cells and HCT-8 cells, respectively.
SKA-31 (5.3 μM; 0-96 hours) reduces HCT-116 cells proliferation when added at time zero at 5.3 μM.
SKA-31 triggers apoptosis in HCT-116 cells at 5 μM, and the effect is smaller in HCT-8 cells at 45 μM.
SKA-31 increases the percentage of cells in G0/G1 phase in HCT-116 and HCT-8 cell lines at 5 μM and 45 μM, respectively.
SKA-31 further activates Caspase 3 and reduces Akt phosphorylation induced by CDDP.
SKA-31 has a synergic effect with CDDP also on the inhibition of HCT-116 cell proliferation.
Cell Viability Assay
| Cell Line: | HCT-116 cells, HCT-8 cells |
| Concentration: | |
| Incubation Time: | 24 hours |
| Result: | Reduced cell viability with IC 50s of 5.3 μM , 46.9 μM in HCT-116 and HCT-8, respectively. |
Cell Proliferation Assay
| Cell Line: | HCT-116 cells |
| Concentration: | 5.3 μM |
| Incubation Time: | 0-96 hours |
| Result: | Reduced HCT-116 cells proliferation when added at time zero at IC 50S value. |
Apoptosis Analysis
| Cell Line: | HCT-116 cells, HCT-8 cells |
| Concentration: | 5 μM (HCT-116 cells), 45 μM (HCT-8 cells) |
| Incubation Time: | 24 hours |
| Result: | Triggered apoptosis in HCT-116 cells, and the effect was smaller in HCT-8 cells. |
Cell Cycle Analysis
| Cell Line: | HCT-116 cells, HCT-8 cells |
| Concentration: | 5 μM (HCT-116), 45 μM (HCT-8) |
| Incubation Time: | 24 hours |
| Result: | Increased the percentage of cells in G0/G1 phase in HCT-116 and HCT-8 cell lines. |
Western Blot Analysis
| Cell Line: | HCT-116 cells |
| Concentration: | |
| Incubation Time: | 24 hours |
| Result: | Further activated Caspase 3 and reduced Akt phosphorylation when co-treatment with CDDP in HCT-116 cells. |
SKA-31 is not acutely toxic and has good pharmacokinetic properties.
SKA-31 potentiates native KCa3.1 and KCa2.3 in murine carotid endothelium with EC
50
values of 225 nM and 1.6 μM for KCa3.1 and KCa2.3, respectively.
SKA-31 stimulates KCa3.1 and KCa2.3 in vascular endothelial cells and increases acetylcholine-induced endothelium-derived hyperpolarizing factor (EDHF) -mediated vasodilation.
SKA-31 potentiates EDHF-type vasodilations and lowers blood pressure in mice. Injections of SKA-31 (1-30 mg/kg; i.p.) lower MAP over 24 hours in normotensive wild-type mice but not in KCa3.1(-/-) mice (-/-).
| Animal Model: | 16-25 weeks mice |
| Dosage: | 1 mg/kg, 10 mg/kg, and 30 mg/kg |
| Administration: | Intraperitoneal injection |
| Result: | Lower MAP over 24 hours in normotensive wild-type mice but not in KCa3.1(-/-) mice (-/-). |